Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at?

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Davies reports other from Algipharma AS, other from Bayer AG, other from Boehringer Ingelheim Pharma GmbH & Co. KG, other from Galapagos NV, other from ImevaX GmbH, other from Nivalis Therapeutics, Inc., other from ProQR Therapeutics III B.V., other from Proteostasis Therapeutics, INC., other from Raptor Pharmaceuticals, Inc, other from Vertex Pharmaceuticals (Europe) Limited, other from Enterprise, other from Novartis, other from Pulmocide, other from Flatley, other from Nivalis Therapeutics Inc., grants from CF Trust, other from Teva, outside the submitted work.

Conflict of interest: Dr. Alton has nothing to disclose.

Conflict of interest: Dr. Simbo has nothing to disclose.

Conflict of interest: Mr. Murphy has nothing to disclose.

Conflict of interest: Dr. Seth has nothing to disclose.

Conflict of interest: Dr. Williams has nothing to disclose.

Conflict of interest: Mark Somerville has nothing to disclose.

Conflict of interest: Dr. Jolly has nothing to disclose.

Conflict of interest: Dr. Morant has nothing to disclose.

Conflict of interest: Dr. Guest has nothing to disclose.